Rice Hall James & Associates LLC Trims Stake in Insmed Incorporated (NASDAQ:INSM)

Rice Hall James & Associates LLC trimmed its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 4.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 467,541 shares of the biopharmaceutical company’s stock after selling 19,571 shares during the quarter. Rice Hall James & Associates LLC owned about 0.60% of Insmed worth $11,969,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Federated Investors Inc. PA purchased a new position in Insmed during the first quarter worth about $9,825,000. Legal & General Group Plc boosted its holdings in shares of Insmed by 4.5% in the 4th quarter. Legal & General Group Plc now owns 29,336 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 1,263 shares in the last quarter. Emerald Advisers LLC boosted its holdings in shares of Insmed by 52.8% in the 1st quarter. Emerald Advisers LLC now owns 921,527 shares of the biopharmaceutical company’s stock worth $26,789,000 after purchasing an additional 318,482 shares in the last quarter. Norges Bank purchased a new position in shares of Insmed in the 4th quarter worth about $9,955,000. Finally, FMR LLC boosted its holdings in shares of Insmed by 0.6% in the 1st quarter. FMR LLC now owns 11,630,784 shares of the biopharmaceutical company’s stock worth $338,107,000 after purchasing an additional 67,250 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

In other news, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $23.24, for a total value of $278,880.00. Following the completion of the sale, the insider now owns 36,350 shares of the company’s stock, valued at approximately $844,774. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO William Lewis sold 400,000 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $26.00, for a total value of $10,400,000.00. Following the completion of the sale, the chief executive officer now directly owns 480,672 shares of the company’s stock, valued at approximately $12,497,472. The disclosure for this sale can be found here. Insiders own 4.95% of the company’s stock.



Shares of NASDAQ INSM traded up $0.23 during midday trading on Thursday, reaching $15.83. The company had a trading volume of 8,851 shares, compared to its average volume of 1,519,810. Insmed Incorporated has a one year low of $11.31 and a one year high of $33.13. The company has a debt-to-equity ratio of 1.01, a quick ratio of 7.31 and a current ratio of 7.54. The company’s fifty day simple moving average is $21.59. The company has a market cap of $1.41 billion, a PE ratio of -3.76 and a beta of 2.78.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $30.00 million during the quarter, compared to the consensus estimate of $26.30 million. As a group, research analysts anticipate that Insmed Incorporated will post -3.02 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Insmed from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Wednesday, July 17th. BidaskClub cut Insmed from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 17th. Finally, ValuEngine cut Insmed from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $36.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Story: What are Bollinger Bands?

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.